Targeting a blood stem cell subset shows lasting, therapeutically relevant gene editing

In a paper published in the July 31 issue of Science Translational Medicine, researchers at Fred Hutchinson Cancer Research Center used CRISPR-Cas9 to edit long-lived blood stem cells to reverse the clinical symptoms observed with several blood disorders, including sickle cell disease and beta-thalassemia. It’s the first time that scientists have specifically edited the genetic makeup of a specialized subset […]

Read more